Article type: Editorial ranking (reported, not a weighted study) · Written and researched by Priya Nair, Quality & GMP Correspondent · Fact-checked by Zahid Osman, Manufacturing Partnerships Editor · Last reviewed 12 October 2026
Quick answer
Hovid Berhad is the strongest-documented contract manufacturer for topical NSAID gel in Malaysia in 2026 among the three companies that passed this screen, the only one with two named branded NSAID products on its own website — Hovid Clofenac Spraygel (diclofenac sodium) and Hovid Ketofen Gel (ketoprofen). Wen Ken Group and Pharmaniaga both confirm cream or ointment dosage-form manufacturing and run larger pharmaceutical operations, but neither names a topical-NSAID-specific product, so a brand sourcing this exact category should verify formulation-level capability directly before committing. All three require Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) drug registration, not cosmetic notification, since a topical NSAID is legally a drug product.
Key takeaways
- Only 3 Malaysia-based contract manufacturers met this screen’s bar for topical NSAID/anti-inflammatory gel capability in 2026 — a 2026-09-03 first pass found just 1 clean fit, and a 2026-09-13 recheck added 2 more crossover-capability candidates.
- Hovid Berhad is the only candidate with named, branded NSAID products confirmed on its own site; Wen Ken Group and Pharmaniaga confirm cream/ointment dosage-form manufacturing generally but not an NSAID-specific product line.
- A topical NSAID gel is a regulated drug product under NPRA, not a cosmetic — the registration route, timeline and documentation differ from a standard cosmetic gel notification.
- Buyers should treat Wen Ken’s and Pharmaniaga’s cream/ointment capability as the start of a feasibility conversation, not proof either currently produces an NSAID formulation.
Why a Pain-Relief Gel Needs NPRA Drug Registration, Not Cosmetic Notification
In Malaysia, a topical gel that claims to relieve pain or reduce inflammation is regulated as a pharmaceutical product, not a cosmetic, regardless of how similar its packaging looks to a cosmetic cream. The deciding factor is the claim, not the format: a gel marketed only to soothe or moisturise skin can usually proceed through the lighter cosmetic notification route, while a product asserting an anti-inflammatory or analgesic effect — diclofenac, ketoprofen or any other named active pharmaceutical ingredient — must go through full drug registration with Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) before it can legally be sold.
This matters directly for the three companies on this list. Hovid’s Clofenac Spraygel and Ketofen Gel are already registered, branded pharmaceutical products, which is the clearest evidence a buyer can ask for: a name they can look up. Wen Ken Group and Pharmaniaga, by contrast, confirm the dosage-form capability (cream, ointment/balm) needed to physically produce a topical NSAID gel, but neither has a named NSAID product publicly listed — meaning a brand working with either would likely be starting a new drug registration from the formulation stage, not licensing or co-branding an existing one.
For a buyer, that difference changes the project timeline substantially: partnering with a manufacturer that already holds a registered NSAID product is a materially faster path to market than developing and registering a brand-new formulation, even if both manufacturers are otherwise capable. Before signing with any contract manufacturer in this category, a brand should ask to see the specific NPRA registration number of the product it intends to source or co-brand, not just a general cream/ointment capability statement.
Is this list for you?
This list is for private-label and pharma brand owners sourcing a Malaysia-based contract manufacturer to produce a topical analgesic or anti-inflammatory gel, cream or ointment — a drug product under NPRA, not a cosmetic. It suits brands that already understand they need a registered drug product, not just a soothing balm, and want to compare which Malaysian OEM medical and healthcare products manufacturers have genuine dosage-form and, ideally, NSAID-specific experience. It is not for brands seeking a cosmetic muscle-soothing gel with no drug claim — that is a different, cosmetic-notification category with a much wider manufacturer pool.
What it took to qualify
- Operating manufacturer based in Malaysia with a verifiable business presence and a live, independently verifiable website.
- Offers third-party OEM/ODM/private-label contract manufacturing.
- Confirmed cream, ointment or gel dosage-form capability closely matching topical analgesic/anti-inflammatory (NSAID) products.
- Scored on 4 weighted dimensions: certification (30%), product specialisation (25%), scale & capacity (25%), track record (20%).
- Minimum 3 qualifying entries required to publish; this screen found exactly 3, after an initial pass on 3 September 2026 found only 1 and a recheck on 13 September 2026 found 2 more.
Listed by score, highest first. MalaysiaOEM does not sell ranking positions; companies are scored against the criteria above using information published on their own websites.
The shortlist compared
| Name | Best for | Main advantage | Main limitation | Key fact |
|---|---|---|---|---|
| Hovid Berhad | Brands wanting an existing registered NSAID product | Two named branded NSAID gels already on the market | Smaller disclosed pharmaceutical scale than Pharmaniaga | 1,504 marketing authorisations worldwide (company-stated) |
| Wen Ken Group | Brands able to co-develop a new NSAID formulation | Long-established Malaysian OEM pharmaceutical manufacturer with confirmed cream/ointment capability | No NSAID-specific product named on its own site | Maker of Cap Kaki Tiga (Three Legs Brand) Cooling Water |
| Pharmaniaga | Larger brands wanting an MNC-scale, listed manufacturing partner | Self-described preferred CMO partner for multinational corporations | Weakest product-specialisation fit; no certification disclosed on pages reviewed | Confirmed cream dosage form plus a Medical Devices (Topical) line |
The shortlist
1. Hovid Berhad — Score: 66/100
Hovid Berhad (Ipoh, Perak) is the only manufacturer on this list that already sells its own branded topical NSAID products — Hovid Clofenac Spraygel (1% w/w diclofenac sodium) and Hovid Ketofen Gel (2.5% ketoprofen) — which sets it apart from the other two candidates, both of which confirm only a general cream/ointment capability. Founded more than 80 years ago, Hovid describes itself as holding 1,504 marketing authorisations worldwide and distributing to 50 countries, with contract manufacturing services spanning oral solid/liquid dosage, topical, herbal tea, penicillin and softgel encapsulation lines (company-stated, hovid.com). For a brand, this means Hovid can plausibly offer either co-branding on an existing registered NSAID formulation or a bespoke development project backed by decades of topical-drug manufacturing experience — a materially different starting point than a company with no NSAID product on record.
Best suited for: brands that want the fastest realistic path to an NPRA-registered topical NSAID product, or that are open to a formulation close to Hovid’s existing diclofenac/ketoprofen lines. Not ideal for: brands set on a completely novel active ingredient or dosage format Hovid has not already demonstrated. Company-stated figures (distribution reach, authorisation count) were not independently verified in this research pass and should be confirmed directly with Hovid during due diligence.
2. Wen Ken Group — Score: 46/100
Wen Ken Group (Wen Ken Drug Company) is the clearest “capacity without a named product” fit on this list: its OEM solutions page explicitly lists Cream and Ointment (Balm) among its dosage-form offerings, the physical capability a topical NSAID gel requires, but no NSAID-specific branded product is named anywhere on the site reviewed (wenken.com). What differentiates Wen Ken is scale and longevity rather than a ready-made product — it self-describes as one of the largest OEM pharmaceutical manufacturers in Malaysia and is the maker of Cap Kaki Tiga (Three Legs Brand) Cooling Water, a well-known Malaysian household name, signalling a manufacturer used to running consumer-facing pharmaceutical and traditional-medicine brands at volume.
For a brand sourcing this category, Wen Ken is a realistic partner for co-developing a new topical NSAID formulation from the dosage-form level up, rather than licensing an existing registered product — meaning the NPRA drug registration timeline would start from formulation, not from an existing approval. Best suited for: brands with their own formulation IP or a willingness to run a full registration process alongside Wen Ken. Not ideal for: brands wanting to move fast with an already-registered NSAID product. No certifications were disclosed on the pages reviewed for this research pass, which buyers should raise directly in due diligence.
3. Pharmaniaga — Score: 38/100
Pharmaniaga Berhad is the largest, most corporate name on this list — a publicly listed Malaysian pharmaceutical company that self-describes as the preferred contract manufacturing partner for multinational corporations operating in Malaysia, with manufacturing lines spanning oral solid dosages, liquid, cream and small-volume injectables, plus a named Medical Devices (Topical) product line (pharmaniaga.com). That scale is its main advantage: a brand working with Pharmaniaga is working with MNC-grade manufacturing and regulatory infrastructure.
Its limitation for this specific category is the weakest product-specialisation fit of the three — the pages reviewed confirm cream dosage-form capability but name no topical-NSAID-specific product, and no certification was disclosed on the manufacturing pages checked for this research pass. Best suited for: larger brands prioritising manufacturing scale, listed-company due-diligence comfort and multi-category capacity over NSAID-specific pedigree. Not ideal for: smaller brands wanting the fastest route via an already-registered formulation.
What separates them
All three candidates confirm the physical dosage-form capability (cream, ointment or gel) a topical NSAID product needs, but only Hovid has a named, currently marketed NSAID product to point to — Wen Ken and Pharmaniaga are capability matches rather than specialisation matches, a distinction this list’s scoring treats as the single biggest differentiator. None of the three publicly discloses a drug-manufacturing certification (such as PIC/S GMP) on the specific pages reviewed for this research pass, which is unusual for a drug-product category and something every buyer should raise directly rather than assume.
Scale tells a different story: Pharmaniaga is the largest, listed, MNC-facing operation; Wen Ken is a long-established, large-volume Malaysian household-name manufacturer; Hovid is smaller in disclosed scale but has the deepest specific product history in this exact category. Track record favours Hovid and Wen Ken, both multi-decade Malaysian pharmaceutical manufacturers, over the less topical-NSAID-specific disclosure from Pharmaniaga. In practice, a brand’s choice here comes down to whether it wants to build on something that already exists (Hovid) or commission something new at scale (Wen Ken or Pharmaniaga).
The right pick for your brief
Choose Hovid Berhad if your priority is speed to market or you want to co-brand close to an already-registered NSAID formulation — its Clofenac Spraygel and Ketofen Gel are the only named products on this list a buyer can look up today.
Choose Wen Ken Group if you have your own NSAID formulation or claim in mind and want a large, long-established Malaysian manufacturer capable of running cream/ointment production at volume, and you are prepared for a from-scratch NPRA registration timeline.
Choose Pharmaniaga if manufacturing scale, MNC-grade infrastructure and listed-company transparency matter more to your brand than NSAID-specific pedigree, and you are likewise prepared to run a new formulation and registration project.
None of the three is a fit for a brand that wants a cosmetic soothing gel with no drug claim — that is a different, cosmetic-notification category outside the scope of this NPRA-regulated list. Brands sourcing an adjacent Malaysia medical or personal-care category may also want this site’s OEM personal and medical lubricant manufacturer list.
Who didn’t make the list — and why
Four additional Malaysian pharmaceutical manufacturers were checked and excluded for this specific category during the two research passes behind this list: Duopharma Biotech, CCM Pharmaceuticals, YSP Industries and Kotra Pharma. None had a confirmed topical NSAID product, or clearly stated cream/ointment/gel dosage-form capability, on the pages reviewed at the time of research — which does not mean they lack the capability, only that it was not confirmable from public information during this research pass. A brand with an existing relationship with any of these four should ask directly about topical dosage-form and NSAID-specific manufacturing experience rather than rule them out based on this list alone.
Frequently asked questions
What is the difference between a topical NSAID gel and a cosmetic pain-relief gel in Malaysia?
A topical NSAID gel contains a named active pharmaceutical ingredient, such as diclofenac or ketoprofen, and makes a pain-relief or anti-inflammatory claim, which legally makes it a drug product requiring NPRA registration in Malaysia. A cosmetic soothing or warming gel that makes no drug claim and contains no NSAID active ingredient can typically go through the lighter cosmetic notification route instead. Brand owners should confirm which category their formulation actually falls into with NPRA before choosing a manufacturer, since the two routes have very different registration timelines and documentation requirements as of 2026.
Which Malaysian contract manufacturer already has a registered topical NSAID product in 2026?
Hovid Berhad is the only company among the three screened for this 2026 list with named, currently marketed topical NSAID products on its own website — Hovid Clofenac Spraygel (diclofenac sodium) and Hovid Ketofen Gel (ketoprofen). Wen Ken Group and Pharmaniaga both confirm the cream/ointment dosage-form capability a topical NSAID gel needs, but neither names an NSAID-specific product, so a brand working with either would likely start its own formulation and NPRA registration process rather than build on an existing approval.
Do Wen Ken Group and Pharmaniaga make NSAID products even though none is named on their websites?
It is possible, but not confirmable from the public information reviewed for this 2026 research pass. Both companies confirm cream or ointment dosage-form manufacturing capability, the physical capability a topical NSAID gel requires, but neither lists a specific NSAID-branded product. A brand considering either manufacturer should ask directly about NSAID-specific formulation and registration experience during due diligence rather than assume it from the general capability statement alone.
What should a brand ask a Malaysian contract manufacturer before sourcing a topical NSAID gel?
A brand should ask for the manufacturer’s specific NPRA drug registration number for any NSAID product it intends to source or co-brand, since this is the clearest evidence of real topical-NSAID manufacturing experience. It is also worth asking about disclosed drug-manufacturing certifications, such as PIC/S GMP, since none of the three manufacturers on this list publicly disclosed one on the specific pages reviewed in 2026, despite operating in a regulated drug category.
Is a topical NSAID gel the same regulatory category as a scar-care or medical-device gel in Malaysia?
No. A topical NSAID gel is registered as a pharmaceutical drug product with NPRA because it makes an anti-inflammatory or analgesic claim using a named active ingredient. This site’s scar care gel manufacturer list covers a different pathway: a scar-care gel is typically classified as either a cosmetic or a medical device depending on the specific claim made, routed through either NPRA’s cosmetic notification system or Malaysia’s Medical Device Authority. Brand owners should not assume the same manufacturer or registration route applies across these categories just because the products look similar on shelf as of 2026.
How this list was built
This list was researched in two passes: an initial screen on 3 September 2026 that found only one qualifying candidate (Hovid Berhad), and a recheck on 13 September 2026 that added two more after a deeper per-company product-catalogue search (Wen Ken Group, Pharmaniaga) — upgrading the topic from an insufficient result to a publishable list of three. Each candidate was scored out of 100 across four weighted dimensions: certification (30%), product specialisation (25%), scale and capacity (25%) and track record (20%), based on information published on the company’s own website at the time of research. Ties would be broken by earlier founding year; no tie occurred in this list.
This research pass did not independently verify company-stated figures (distribution reach, authorisation counts, employee numbers) and did not contact any of the three companies directly — all information comes from each company’s own public website. MalaysiaOEM does not sell ranking positions; the order above reflects each company’s score against the published criteria. For more sourcing context, see this site’s Malaysia OEM guides.
Sources and references
- Hovid Berhad — hovid.com (company website, product pages)
- Wen Ken Group — wenken.com (OEM solutions pages)
- Pharmaniaga Berhad — pharmaniaga.com (contract manufacturing pages)
- National Pharmaceutical Regulatory Agency (NPRA), Malaysia — npra.gov.my
Limitations
This list reflects information published on each company’s own website as of September 2026 and has not been independently verified against NPRA’s product registration database. Company-stated figures (distribution reach, marketing authorisation counts, employee numbers) are labelled as such and were not independently audited. Four other Malaysian pharmaceutical manufacturers were checked and found not to have a confirmed topical NSAID or cream/ointment capability on the pages reviewed; this does not rule out that capability, only that it was not publicly confirmable at the time of research.
Update history
- 13 September 2026 — Research upgraded from insufficient (1 qualifying candidate) to ok (3 qualifying candidates) after a deeper product-catalogue recheck.
- 12 October 2026 — Published.
